U.S. flag

An official website of the United States government

Display Settings:

Format

Send to:

Choose Destination
  • Quoted phrase not found.
  • See the search details.
Entrectinib (Rozlytrek): CADTH Reimbursement Recommendation: Indication: For the treatment of adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation and with no satisfactory treatment options [Internet].

Entrectinib (Rozlytrek): CADTH Reimbursement Recommendation: Indication: For the treatment of adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation and with no satisfactory treatment options [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Table of contents

1.

Entrectinib (Rozlytrek): CADTH Reimbursement Recommendation: Indication: For the treatment of adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation and with no satisfactory treatment options [Internet].

Supplemental Content

Search details

See more...

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...